EYEG
EyeGate Pharmaceuticals, Inc. [EYEG] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EYEG Stock Summary
Top EYEG Correlated Resources
EYEG
Top 10 Correlated ETFs
EYEG
Top 10 Correlated Stocks
EYEG
In the News
EYEG Financial details
EYEG Financial Performance
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
| Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.44 | -0.53 | -0.37 | -0.35 | -0.42 | |
| Operating cash flow per share | -0.38 | -0.38 | -0.37 | -0.37 | -0.32 | |
| Free cash flow per share | -0.38 | -0.38 | -0.38 | -0.37 | -0.32 | |
| Cash per share | 0.64 | 0.26 | 0.95 | 0.52 | 1.57 | |
| Book value per share | 1.31 | 1.54 | 1.82 | 1.48 | 2.46 | |
| Tangible book value per share | 0.07 | -1.37 | -0.08 | -0.39 | 0.59 | |
| Share holders equity per share | 1.31 | 1.54 | 1.82 | 1.48 | 2.46 | |
| Interest debt per share | 0.07 | 0.07 | 0.08 | 0.04 | 0.07 | |
| Market cap | 17.83M | 22.42M | 34.63M | 25.71M | 15.89M | |
| Enterprise value | 15.23M | 21.56M | 28.54M | 22.35M | 5.3M | |
| P/E ratio | -2.22 | -2.32 | -3.35 | -2.6 | -1.34 | |
| Price to sales ratio | 0 | 1.86K | 0 | 0 | 0 | |
| POCF ratio | -10.24 | -13.11 | -13.48 | -9.75 | -7 | |
| PFCF ratio | -10.24 | -12.96 | -13.18 | -9.73 | -7 | |
| P/B Ratio | 2.99 | 3.2 | 2.73 | 2.46 | 0.92 | |
| PTB ratio | 2.99 | 3.2 | 2.73 | 2.46 | 0.92 | |
| EV to sales | 0 | 1.79K | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -7.62 | -8.97 | -11.11 | -9.11 | -1.79 | |
| EV to operating cash flow | -8.75 | -12.61 | -11.11 | -8.48 | -2.34 | |
| EV to free cash flow | -8.75 | -12.47 | -10.86 | -8.46 | -2.34 | |
| Earnings yield | -0.11 | -0.11 | -0.07 | -0.1 | -0.19 | |
| Free cash flow yield | -0.1 | -0.08 | -0.08 | -0.1 | -0.14 | |
| Debt to equity | 0.06 | 0.05 | 0.04 | 0.03 | 0.03 | |
| Debt to assets | 0.04 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Net debt to EBITDA | 1.3 | 0.36 | 2.37 | 1.37 | 3.58 | |
| Current ratio | 3.76 | 1.02 | 4.9 | 3.07 | 6.06 | |
| Interest coverage | 0 | -600.45 | -3.76K | -1.35K | 0 | |
| Income quality | 0.87 | 0.71 | 1 | 1.07 | 0.77 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 125.59 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 83.84 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.61 | 0.87 | 0.64 | 0.73 | 0.52 | |
| Capex to operating cash flow | 0 | 0.01 | 0.02 | 0 | 0 | |
| Capex to revenue | 0 | -1.66 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -2.22 | -5.48 | -0.46 | 0 | |
| Stock based compensation to revenue | 0 | 16.02 | 0 | 0 | 0 | |
| Graham number | 3.61 | 4.29 | 3.9 | 3.41 | 4.82 | |
| ROIC | -0.32 | -0.34 | -0.19 | -0.28 | -0.17 | |
| Return on tangible assets | -0.56 | -1.24 | -0.35 | -0.5 | -0.24 | |
| Graham Net | -0.08 | -1.52 | -0.17 | -0.53 | 0.42 | |
| Working capital | 2.57M | 37.82K | 5.57M | 2.98M | 9.91M | |
| Tangible asset value | 323.14K | -6.22M | -523.52K | -2.75M | 4.15M | |
| Net current asset value | 213.86K | -6.35M | -944.52K | -3.23M | 3.72M | |
| Invested capital | 0.06 | 0.05 | 0.04 | 0.03 | 0.03 | |
| Average receivables | 2.15K | 46.87K | 119.04K | 229.14K | 155.58K | |
| Average payables | 76.91K | 247.15K | 446.06K | 374.83K | 358.6K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 678.97 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0.13 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.34 | -0.35 | -0.2 | -0.24 | -0.17 | |
| Capex per share | 0 | 0 | -0.01 | 0 | 0 |
EYEG Frequently Asked Questions
What is EyeGate Pharmaceuticals, Inc. stock symbol ?
EyeGate Pharmaceuticals, Inc. is a US stock , located in Waltham of Massachusetts and trading under the symbol EYEG
What is EyeGate Pharmaceuticals, Inc. stock quote today ?
EyeGate Pharmaceuticals, Inc. stock price is $34.77 today.
Is EyeGate Pharmaceuticals, Inc. stock public?
Yes, EyeGate Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 97
- Market Capitalization 64.66M
- Employee 14
- CEO Mr. Stephen From
- Headquarters Waltham,MASSACHUSETTS,US
- IPO Date 2015-02-13
-
Website
http://www.eyegatepharma.com 
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
